HAVEN 2 Updated Analysis: Multicentre, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Paediatric Patients with Haemophilia A with Inhibitors

被引：0
|
作者：
Young, G. [1 ]
Sidonio, R. F. [2 ,3 ]
Liesner, R. [4 ]
Oldenburg, J. [5 ]
Chang, T. [6 ]
Uguen, M. [7 ]
Dhalluin, C. [7 ]
Schmitt, C. [7 ]
Levy, G. G. [6 ]
Shima, M. [8 ]
Mahlangu, J. [9 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Great Ormond St Hosp Sick Children, London, England
[5] Univ Klinikum Bonn, Bonn, Germany
[6] Genentech Inc, San Francisco, CA USA
[7] F Hoffmann La Roche Ltd, Basel, Switzerland
[8] Nara Med Univ Hosp, Kashihara, Nara, Japan
[9] Univ Witwatersrand, Johannesburg, South Africa
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
emicizumab; haemophilia A; inhibitors; paediatric;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-OR-0
引用
收藏
页码：20 / 21
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics (PK), pharmacodynamics (PD) and PK/PD relationships of emicizumab in persons with haemophilia a (PWHA) with inhibitors from adolescent/adult (HAVEN 1) and paediatric (HAVEN 2) phase 3 studies
    Schmitt, C.
    Adamkewicz, J.
    Xu, J.
    Chang, T.
    Petry, C.
    Calatzis, A.
    Young, G.
    Negrier, C.
    Meeks, S.
    Callaghan, M.
    Levy, G. G.
    HAEMOPHILIA, 2018, 24 : 27 - 28
  • [22] Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A
    Chowdary, Pratima
    Mullins, Eric S.
    Konkle, Barbara A.
    McGuinn, Catherine
    Park, Young Shil
    Stasyshyn, Oleksandra
    Zulfikar, Bulent
    Engl, Werner
    Tangada, Srilatha
    HAEMOPHILIA, 2020, 26 (04) : E168 - E178
  • [23] Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study
    Hide, Michihiro
    Wang, Yi
    Dote, Nobuhito
    Miyakawa, Kou
    Sugiura, Kenkichi
    Ishida, Kazuyuki
    JOURNAL OF DERMATOLOGY, 2023, 50 (11): : 1473 - 1477
  • [24] Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
    Shapiro, Amy
    Castaman, Giancarlo
    Cepo, Katarina
    Poulsen, Lone Hvitfeldt
    Hollensen, Christian
    Matsushita, Tadashi
    Young, Guy
    Zupancic-Salek, Silva
    Jimenez-Yuste, Victor
    BLOOD, 2019, 134
  • [25] Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
    Kempton, Christine
    Trask, Peter
    Parnes, Aric
    Niggli, Markus
    Campinha-Bacote, Avrita
    Callaghan, Michael U.
    O'Connell, Niamh
    Paz-Priel, Ido
    Mahlangu, Johnny N.
    HAEMOPHILIA, 2021, 27 (02) : 221 - 228
  • [26] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    D. H. Palmer
    Y. T. Ma
    M. Peck-Radosavljevic
    P. Ross
    J. Graham
    L. Fartoux
    A. Deptala
    M. Studeny
    D. Schnell
    J. Hocke
    A-B. Loembé
    T. Meyer
    British Journal of Cancer, 2018, 118 : 1162 - 1168
  • [27] A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
    Palmer, D. H.
    Ma, Y. T.
    Peck-Radosavljevic, M.
    Ross, P.
    Graham, J.
    Fartoux, L.
    Deptala, A.
    Studeny, M.
    Schnell, D.
    Hocke, J.
    Loembe, A-B.
    Meyer, T.
    BRITISH JOURNAL OF CANCER, 2018, 118 (09) : 1162 - 1168
  • [28] Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study
    Hide, Michihiro
    Fukunaga, Atsushi
    Maehara, Junichi
    Eto, Kazunori
    Hao, James
    Vardi, Moshe
    Nomoto, Yuji
    ALLERGOLOGY INTERNATIONAL, 2020, 69 (02) : 268 - 273
  • [29] Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: An interim analysis of an open-label, phase 2 study
    Tsuyuguchi, Kazunari
    Sasaki, Yuka
    Mitarai, Satoshi
    Kurosawa, Ken
    Saito, Yuki
    Koh, Tadaishi
    RESPIRATORY INVESTIGATION, 2019, 57 (04) : 345 - 353
  • [30] SUBCUTANEOUS CONCIZUMAB PROPHYLAXIS IN PATIENTS WITH HAEMOPHILIA A OR B WITH INHIBITORS: EFFICACY AND SAFETY RESULTS BY HAEMOPHILIA SUBTYPE FROM THE PHASE 3 EXPLORER7 TRIAL
    Mathias, M.
    Cepo, K.
    d'Oiron, R.
    Frei-Jones, M.
    Goh, A. -S.
    Odgaard-Jensen, J.
    HAEMOPHILIA, 2023, 29 : 17 - 17
12345